CLAIM #48690 · Pfizer Inc (PFE) · 2025Q4 earnings call · Feb 3, 2026 · due Dec 31, 2026
“We should share later this year, including at ADA, updated data on the amylin, and potential early data for the combination of the amylin plus 3944.”
Chris Boshoff · Chief Scientific Officer
CANNOT_DETERMINE
resolved by a revision, graded at the moved level · official band 5 percent
Committed
share later this year, including at ADA, updated data on the amylin, and potential early data for the combination of the amylin plus 3944
Reported
We will not share yet at ADA data on amylin mono. We expect 24 weeks monotherapy and 28 weeks combination with the amylin and GLP-1 that will be shared in the second half of this year.
How to check this claim
Look at: Disclosure of updated amylin clinical data and early data on amylin + PF-06954523/3944 combination
It came true if: Company or management presents/discusses updated amylin data and/or combination data (e.g., at ADA conference or in press release/call) by year-end 2026
Where: Company press releases, ADA conference presentations, or earnings call transcripts
Verify independently
SEC filings for PFE ↗ · Claim quote is verbatim from the 2025Q4 earnings call.